Mannkind reported $-7696000 in EBITDA for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Dynavax Technologies DVAX:US USD 64.6M 1.88M
Halozyme Therapeutics HALO:US USD 83.06M 29.83M
Immunogen IMGN:US USD -59131000 17.87M
Insmed INSM:US USD -149714000 29.85M
JAZZ PHA JAZZ:US USD -118655000 466.69M
Macrogenics MGNX:US USD 15.21M 37.32M
Mannkind MNKD:US USD -7696000 1.94M
Minerva Neurosciences NERV:US USD -5063000 142K
Novavax NVAX:US USD -228852000 110.01M
Novo Nordisk A Fs NVO:US DKK 18.31B 3.91B
Peregrine Pharmaceuticals PPHM:US USD 4.64M 5.5M
Pfizer PFE:US USD 6.94B 3.94B
Xencor XNCR:US USD -40434000 4.32M